The systemic administration of mTORC1 inhibitors is potentially risky due to serious adverse effects, including immunosuppression.114 Therefore, intradiscal gene and pharmacological therapies targeting mTORC1/RAPTOR suppression are potential biological treatments for degenerative disc disease. The gene discussed is RPTOR; the disease is Intervertebral disk degeneration.